Has Erdafitinib been launched in China?

Erdafitinib (Erdafitinib) is an oral small molecule drug, a tyrosine kinase inhibitor, used to treat a specific type of advanced or metastatic urothelial carcinoma (urothelial carcinoma). The uniqueness of this drug is that it can target and inhibit FGFR (fibroblast growth factor receptor) kinase, thereby blocking abnormal signaling pathways and inhibiting the growth and spread of cancer cells.

Erdafitinib is not currently on the market in China, so patients cannot purchase it domestically and need to purchase erdafitinib through foreign channels. The original drug of erdafitinib is mainly the Hong Kong version of the original drug, with a price of more than 20,000, and needs to be purchased through a Hong Kong pharmacy. The generic drugs are relatively cheaper, mainly the Laos version and the Bangladesh Yaopin International version, with a price of about 1,000 to 2,000, and the ingredients of the original drug and the generic drug are basically the same.

FGFR is a type of receptor kinase that is closely related to cell growth and differentiation. In some cancers, especially urothelial cancer, the FGFR gene may be mutated or overexpressed, resulting in abnormal signal transduction, thereby promoting abnormal proliferation of cancer cells. The mechanism of action of erdafitinib is mainly by selectively blocking the activity of FGFR kinase, thereby inhibiting these abnormal signaling pathways and is expected to inhibit the growth of cancer cells.

Clinical study results of erdafitinib show that the drug shows significant efficacy in some patients with urothelial cancer, especially those with FGFR gene mutations or overexpression. However, like all drugs, it may be accompanied by some side effects, such as high blood pressure, phosphate metabolism disorders, etc., so the patient's physical condition needs to be closely monitored during use.

It is important to note that patients should undergo genetic testing before taking erdafitinib to determine whether they are suitable for treatment with this drug. This personalized treatment plan helps to improve the pertinence and effectiveness of treatment.